Orphan Drug Monopoly Extension
Federal incentives meant for neglected diseases get used to privatize widely available medicines.
"Take a free compound, rename it, and re-rent it."
What is Orphan Drug Monopoly Extension? Federal incentives meant for neglected diseases get used to privatize widely available medicines. Regulatory loopholes are revenue if you read them creatively.
Repackaged decades-old drugs granted orphan exclusivity at 50–100x prices.
Regulatory loopholes are revenue if you read them creatively.
Tighten orphan eligibility. Outcome-tied price caps.
Flip the incentive. Watch the side-effect move.
Federal incentives meant for neglected diseases get used to privatize widely available medicines. Caught in the wild: Repackaged decades-old drugs granted orphan exclusivity at 50–100x prices.
In the room: Regulatory loopholes are revenue if you read them creatively.
Counter-move from the Atlas: Tighten orphan eligibility.
Pick a reaction to Orphan Drug Monopoly Extension
One tap. We'll point you at the most useful next surface based on how this hits.
The full taxonomy entry
Every concept in the Atlas uses the same structure — so Orphan Drug Monopoly Extension can be compared, recombined, and cited like an element on a periodic table.
- Business
- Leadership
- Government
- Healthcare
- Education
- Sales
- Marketing
- AI
- Negotiation
- Media
- Public Policy
- Relationships
- Where in our org would Orphan Drug Monopoly Extension most often show up unnoticed?
- Which metric, ritual, or contract clause quietly rewards Orphan Drug Monopoly Extension?
- If we removed every payoff for Orphan Drug Monopoly Extension, what behavior would replace it?
- Who benefits when Orphan Drug Monopoly Extension persists — and who pays the cost?
- People defend the status quo using the language of orphan drug monopoly extension.
- Decisions cluster around the easiest narrative rather than the strongest evidence.
- New data changes the slide deck but not the decision.
- Anyone naming the pattern is treated as the problem.
Every Atlas entry is a node in a knowledge graph. See the related rail below to follow the connections.
See Orphan Drug Monopoly Extension through 2 lenses
Each layer of the Incentives OS reframes this concept with its own thinkers, vocabulary, and diagnostic question.
Do you actually know Orphan Drug Monopoly Extension?
Three quick questions. Result is saved into your review streak — come back when the term is due to lock it in.
Which best describes Orphan Drug Monopoly Extension?
Worked example, counter-example & concept map
On-demand AI analysis grounded in the Lab's research. Cached on your device after first run.
When you encounter Orphan Drug Monopoly Extension, your amygdala tags it as threat before your reasoning brain even knows what happened — and threat wins the first move.
Threat detection, fear, social pain, loss aversion, fast emotional tagging. Loss feels roughly twice as bad as equivalent gain feels good. Social rejection lights up the same circuits as physical pain.
See Amygdala in the Brain Atlas →Picked for you, from the Atlas
Ranked by shared learning paths, overlapping chips, and what you've saved.
Productivity targets compress visits, raising misdiagnosis and burnout.
A federal mandate intended to lower drug costs for the poor became a profit engine for hospitals and contract pharmacies.
Liability exposure pushes clinicians to order tests for legal protection rather than clinical need.
Federal reimbursement rules incentivize cycling seniors through hospitalizations to upgrade billing categories.
Paying providers per procedure rewards more procedures, not better outcomes.
Systems paid per filled bed have weak incentives to invest in prevention or community health.
Send the card, not just the link
A pre-rendered social card with the title, eyebrow, and URL. Copy the link, post it anywhere, or download the SVG for slides.
More definitions to follow
Every term in the Atlas connects to a dozen others. Pick any of these and see where it takes you.
Wish → Outcome → Obstacle → Plan. A goal-setting protocol from Oettingen.
It's better because it's newer.
Asking the other side to disprove an unsupported claim.
Believing a specific scenario is more likely than its more general one.
How much we value the present over the future.
Quantitative measures of model behavior across groups.
An automatic action triggered by a stable cue — built through repetition.
Customers hire products to do a job in their life.
Today's metrics achieved by quietly borrowing from tomorrow.
A small number of items account for most of the value.
Technologies grow slowly, then explode, then plateau.
The fine-grained sensory qualities of internal experience — brightness, distance, volume, location.